Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis
Torgutalp M, Rios Rodriguez V, Dilbaryan A, Proft F, Protopopov M, Verba M, Rademacher J, Haibel H, Sieper J, Rudwaleit M, Poddubnyy D (2022)
Annals of the rheumatic diseases 81(9): 1252-1259.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
1252.full.pdf
961.68 KB
Autor*in
Torgutalp, Murat;
Rios Rodriguez, Valeria;
Dilbaryan, Ani;
Proft, Fabian;
Protopopov, Mikhail;
Verba, Maryna;
Rademacher, Judith;
Haibel, Hildrun;
Sieper, Joachim;
Rudwaleit, MartinUniBi;
Poddubnyy, Denis
Einrichtung
Abstract / Bemerkung
OBJECTIVE: The objective of the current study was to analyse the association between treatment with tumour necrosis factor inhibitors (TNFi) and radiographic spinal progression in patients with axial spondyloarthritis (axSpA) from a long-term inception cohort.; METHODS: A total of 243 patients with axSpA from the German Spondyloarthritis Inception Cohort with at least two sets of spinal radiographs obtained at least 2 years apart during a 10-year follow-up were included. Spinal radiographs were evaluated by three trained and calibrated readers according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). The association between the current TNFi, previous TNFi and radiographic spinal progression defined as the absolute mSASSS change score over 2 years was analysed using longitudinal generalised estimating equations analysis.; RESULTS: TNFi treatment in the current 2-year interval was not associated with retardation of radiographic spinal progression (beta=-0.02 (95% CI -0.37 to 0.34) and -0.17 (95% CI -0.54 to 0.20) for any and ≥12 months treatment duration, respectively, adjusted for sex, the Ankylosing Spondylitis Disease Activity Score, smoking, presence of definite radiographic sacroiliitis, mSASSS at baseline and non-steroidal anti-inflammatory drug intake). TNFi treatment in the previous 2-year interval, was, however, significantly associated with reduction of mSASSS progression, which was especially evident in patients who received TNFi in the previous and in the current intervals: beta=-0.58 (95% CI -1.02 to -0.13), adjusted for the same variables.; CONCLUSION: TNFi treatment was associated with a time-shifted effect on radiographic spinal progression in axSpA that became evident between years 2 and 4 after treatment initiation. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Erscheinungsjahr
2022
Zeitschriftentitel
Annals of the rheumatic diseases
Band
81
Ausgabe
9
Seite(n)
1252-1259
Urheberrecht / Lizenzen
eISSN
1468-2060
Page URI
https://pub.uni-bielefeld.de/record/2963951
Zitieren
Torgutalp M, Rios Rodriguez V, Dilbaryan A, et al. Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis. Annals of the rheumatic diseases. 2022;81(9):1252-1259.
Torgutalp, M., Rios Rodriguez, V., Dilbaryan, A., Proft, F., Protopopov, M., Verba, M., Rademacher, J., et al. (2022). Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis. Annals of the rheumatic diseases, 81(9), 1252-1259. https://doi.org/10.1136/annrheumdis-2022-222324
Torgutalp, Murat, Rios Rodriguez, Valeria, Dilbaryan, Ani, Proft, Fabian, Protopopov, Mikhail, Verba, Maryna, Rademacher, Judith, et al. 2022. “Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis”. Annals of the rheumatic diseases 81 (9): 1252-1259.
Torgutalp, M., Rios Rodriguez, V., Dilbaryan, A., Proft, F., Protopopov, M., Verba, M., Rademacher, J., Haibel, H., Sieper, J., Rudwaleit, M., et al. (2022). Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis. Annals of the rheumatic diseases 81, 1252-1259.
Torgutalp, M., et al., 2022. Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis. Annals of the rheumatic diseases, 81(9), p 1252-1259.
M. Torgutalp, et al., “Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis”, Annals of the rheumatic diseases, vol. 81, 2022, pp. 1252-1259.
Torgutalp, M., Rios Rodriguez, V., Dilbaryan, A., Proft, F., Protopopov, M., Verba, M., Rademacher, J., Haibel, H., Sieper, J., Rudwaleit, M., Poddubnyy, D.: Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis. Annals of the rheumatic diseases. 81, 1252-1259 (2022).
Torgutalp, Murat, Rios Rodriguez, Valeria, Dilbaryan, Ani, Proft, Fabian, Protopopov, Mikhail, Verba, Maryna, Rademacher, Judith, Haibel, Hildrun, Sieper, Joachim, Rudwaleit, Martin, and Poddubnyy, Denis. “Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis”. Annals of the rheumatic diseases 81.9 (2022): 1252-1259.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung-Nicht kommerziell 4.0 International (CC BY-NC 4.0):
Volltext(e)
Name
1252.full.pdf
961.68 KB
Access Level
Open Access
Zuletzt Hochgeladen
2022-08-16T11:22:38Z
MD5 Prüfsumme
db69dc0281fe94bb14c38ce64ea27eeb
Link(s) zu Volltext(en)
Access Level
Open Access
Daten bereitgestellt von European Bioinformatics Institute (EBI)
Zitationen in Europe PMC
Daten bereitgestellt von Europe PubMed Central.
References
Daten bereitgestellt von Europe PubMed Central.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Quellen
PMID: 35697486
PubMed | Europe PMC
Suchen in